Datapoint: Jakafi Approved for Chronic GVHD

The FDA last week approved Incyte Corp.’s JAK inhibitor Jakafi for the treatment of chronic graft-versus-host disease (GVHD) in patients that have not responded to one or two other lines of systemic therapy. Jakafi, which is already approved for the acute form of the disease, currently holds covered or better status for 70% of all insured lives.

SOURCE: MMIT Analytics, as of 9/23/21

0

0

0 Comments

0

0

• Datapoint